You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
AstraZeneca
Moodys
Baxter
Medtronic

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 9,309,275

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,309,275
Title:3\'-deoxy nucleosides for the treatment of HCV
Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3\'-deoxy nucleoside compounds according to Formula 3001a or 3001b: ##STR00001## or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base.sup.1 and Base.sup.2 are as provided herein.
Inventor(s): Stewart; Alistair James (Lincoln, MA), Moussa; Adel M. (Burlington, MA), Mayes; Benjamin Alexander (Boston, MA), Alexandre; Francois-Rene (Montpellier, FR), Surleraux; Dominique (Wauthier-Braine, BE), Parsy; Christophe Claude (Jacou, FR), Pierra; Claire (Montarnaud, FR), Dukhan; David (Saint Gely du Fesc, FR), Gosselin; Gilles (Montpellier, FR)
Assignee: IDENIX PHARMACEUTICALS LLC (Cambridge, MA) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES (Montpellier, FR)
Application Number:14/195,388
Patent Claims:see list of patent claims

Details for Patent 9,309,275

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial IDENIX PHARMACEUTICALS LLC (Cambridge, MA) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES (Montpellier, FR) 2039-03-29 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial IDENIX PHARMACEUTICALS LLC (Cambridge, MA) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES (Montpellier, FR) 2039-03-29 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial IDENIX PHARMACEUTICALS LLC (Cambridge, MA) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES (Montpellier, FR) 2039-03-29 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Medtronic
Boehringer Ingelheim
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.